OTTAWA, Jan. 31, 2020 — Calian Group Ltd. (TSX: CGY) today announces its acquisition of two Ottawa-based health companies, Allphase Clinical Research Services Inc. and Alio Health Services Inc. (collectively, “Allphase/Alio”).
The companies serve the pharmaceutical and medical device industry and the broader health care sector with clinical trial services, specialty medication support and community care and other services, all enabled by an innovative healthcare delivery management software application. The transaction provides Calian’s Health segment with access to innovative services and new customer segments in pharmaceuticals, hospital care and patient support at home.
Established in 2001, Allphase Clinical Research is a full-service contract research organization (CRO) providing high-quality clinical development management and strategy services for pharmaceutical and medical device companies that have products in development or approved and marketed.
Since its launch in 2012, Alio Health Services has grown rapidly in the areas of patient support program (PSP) management and health resource optimization. Alio Health specializes in the design and implementation of comprehensive patient support programs that enhance the patient’s experience throughout their treatment journey. Its services are enabled by Alio’s innovative HOMETM software application which streamlines the scheduling and delivery of health services for hospitals, health care institutions and home care locations. Driven by proprietary systems and HOMETM system automation, Alio’s patient support programs ensure superior quality control and the provision of more cost-effective in-home services.
“We are very pleased to join the Calian team and a larger, innovative market player,” said Jeff Smith, President, Allphase/Alio. “At Allphase and Alio Health, we are focused on creating the best experiences for patients, caregivers and the health care industry. Calian’s scale and market reach will enable Allphase/Alio’s continued expansion within the health sector and support our ability to take our proprietary software products, systems and services to the next level.”
“I am excited to bring Jeff and the entire Allphase/Alio team on board at Calian. This acquisition will accelerate our access to emerging technologies and business in new markets, encompassing hospitals, patient support at home and clinical trial services,” said Gordon McDonald, Vice President, Health, Calian. “As we leverage the HOMETM software application across Calian’s existing health services portfolio, we see significant potential to drive new business and create efficiencies within our current health services.”
The amount paid on closing of $14.5 million is comprised $12 million in cash and 62,054 common shares. Additionally, the agreement contains two earnout payments on the first- and second-year anniversaries, of $6 million and $6 million respectively, based on the achievement of a certain level of EBITDA in each of those periods. Allphase/Alio’s results will be consolidated and reported within Calian’s Health segment.
“This strategic acquisition supports all four pillars of our growth framework. It diversifies our customer base into pharmaceuticals, home care and hospitals, and supports Calian’s innovation agenda with services enabled by sophisticated software. We see opportunities to evolve this software within our Health segment and strengthen Calian’s position in technology-enabled health solutions,” stated Kevin Ford, President and CEO, Calian. “I would like to extend a warm welcome to the Allphase/Alio team, whose addition to Calian will support our health innovation objectives and sales efforts in new markets domestically and globally. At Calian we believe in investing in technologies that can improve the performance of our health system.”
About Allphase/Alio
Allphase Clinical Research Services Inc. and, Alio Health Services Inc. (collectively, “Allphase/Alio”) are Ottawa-based health service companies serving the Canadian market. Founded in 2001, Allphase Clinical Research is a full-service, Contract Research Organization (CRO) providing high-quality clinical development management and strategy services for companies with early-stage to post-market approval products. Alio Health specializes in the design and implementation of comprehensive Patient Support Programs (PSP) that enhance the patient’s experience throughout their treatment journey. Alio Health’s unique and proprietary PSP workflow automation software and systems ensure excellent quality control and provide significant operational cost efficiencies. The companies serve hospitals, clinics, home care locations and large pharmaceutical customers in all major markets in Canada.
À propos de Calian
Nous faisons avancer le monde. Calian® aide les gens à communiquer, à innover, à apprendre et à mener une vie saine et sûre. Chaque jour, nos employés vivent nos valeurs d’engagement envers le client, d’intégrité, d’innovation, de respect et de travail d’équipe pour concevoir des solutions fiables qui résolvent des problèmes complexes. C’est la confiance. Ingénierie. Entreprise stable et en pleine croissance depuis 40 ans, notre siège social se trouve à Ottawa et nos bureaux et projets couvrent les marchés nord-américains, européens et internationaux. Visitez calian.com pour découvrir des solutions innovantes en matière de soins de santé, de communications, d’apprentissage et de cybersécurité.
Les noms de produits ou de services mentionnés dans le présent document peuvent être des marques déposées de leurs propriétaires respectifs.
Demandes de renseignements des médias :[email protected] 613-599-8600 x 2298 Relations avec les investisseursinquiries:[email protected]
CLAUSE DE NON-RESPONSABILITÉ
Certaines informations contenues dans le présent communiqué de presse sont de nature prospective et sont soumises à des risques et incertitudes importants. Les résultats ou événements prévus dans ces déclarations peuvent différer matériellement des résultats ou événements réels. Ces déclarations sont généralement accompagnées de termes tels que “avoir l’intention”, “anticiper”, “croire”, “estimer”, “s’attendre à” ou d’autres termes similaires. Les facteurs susceptibles d’entraîner des résultats ou des événements différents des attentes actuelles comprennent, entre autres : l’impact de la concurrence sur les prix ; la rareté des professionnels qualifiés ; l’impact de l’évolution rapide des technologies et des marchés ; la perte d’activité ou le risque de crédit avec les principaux clients ; les risques techniques sur les projets à prix fixe ; les conditions générales du secteur et du marché et les taux de croissance ; la croissance internationale et les conditions économiques mondiales, y compris les fluctuations des taux de change ; et l’impact des consolidations dans l’industrie des services aux entreprises. Pour de plus amples informations concernant certains de ces facteurs et d’autres, veuillez consulter le dernier rapport annuel de la société et les autres rapports déposés par Calian auprès de la Commission des valeurs mobilières de l’Ontario. Calian décline toute intention ou obligation de mettre à jour ou de réviser les déclarations prévisionnelles, que ce soit en raison de nouvelles informations, d’événements futurs ou autres. Rien ne garantit que les résultats, performances ou réalisations réels exprimés ou sous-entendus dans les déclarations prospectives contenues dans la présente communication se produiront ou, s’ils se produisent, que des avantages pourront en être tirés.
Calian – Siège social – 770 Palladium Drive – Ottawa – Ontario – Canada – K2V 1C8
Tel : 613.599.8600 – Fax : 613-592-3664 – General info email : [email protected]